Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

Morie Gertz, Martha Lacy, D. A. Gastineau, D. J. Inwards, M. G. Chen, Ayalew Tefferi, R. A. Kyle, Mark R Litzow

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

This study investigated the response rate and toxicity of blood cell transplantation as treatment for primary amyloidosis (AL). Twenty-three patients had stem cells collected between November 1995 and September 1998. Conditioning included melphalan and total body irradiation in 16 and melphalan alone in 4. Three patients did not undergo stem cell infusion because of poor performance status. Two died of progressive amyloid at 1 and 3 months. One patient is alive on hemodialysis. Fourteen males and six females (median age, 57 years) underwent transplantation. Renal, cardiac (by echocardiography), peripheral neuropathy or liver amyloidosis occurred in 14, 12, 3, and 1, respectively. Echocardiography demonstrated an interventricular septal thickness ≥15 mm in six patients, five of whom died post transplantation. Three patients died of progressive amyloidosis at 7, 7, and 21 months. Thirteen patients are alive with a follow-up of 3 to 26 months. Twelve (60%) fulfilled the criteria of a hematologic or organ response. Severe gastrointestinal tract toxicity was seen in five (25%). We conclude that blood cell transplantation for amyloidosis had a much higher morbidity and mortality compared with transplantation for myeloma. The best results appear to occur in patients with nephrotic syndrome as the only manifestation of their disease.

Original languageEnglish (US)
Pages (from-to)963-969
Number of pages7
JournalBone Marrow Transplantation
Volume26
Issue number9
StatePublished - 2000

Fingerprint

Stem Cell Transplantation
Blood Cells
Amyloidosis
Melphalan
Transplantation
Cell Transplantation
Therapeutics
Echocardiography
Stem Cells
Whole-Body Irradiation
Nephrotic Syndrome
Peripheral Nervous System Diseases
Primary amyloidosis
Amyloid
Renal Dialysis
Gastrointestinal Tract
Morbidity
Kidney
Mortality
Liver

Keywords

  • Amyloidosis
  • Congestive heart failure
  • Monoclonal protein
  • Multiple myeloma
  • Nephrotic syndrome
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). / Gertz, Morie; Lacy, Martha; Gastineau, D. A.; Inwards, D. J.; Chen, M. G.; Tefferi, Ayalew; Kyle, R. A.; Litzow, Mark R.

In: Bone Marrow Transplantation, Vol. 26, No. 9, 2000, p. 963-969.

Research output: Contribution to journalArticle

@article{b8de4cb88b8a4adfa1faf0b4cab2d113,
title = "Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)",
abstract = "This study investigated the response rate and toxicity of blood cell transplantation as treatment for primary amyloidosis (AL). Twenty-three patients had stem cells collected between November 1995 and September 1998. Conditioning included melphalan and total body irradiation in 16 and melphalan alone in 4. Three patients did not undergo stem cell infusion because of poor performance status. Two died of progressive amyloid at 1 and 3 months. One patient is alive on hemodialysis. Fourteen males and six females (median age, 57 years) underwent transplantation. Renal, cardiac (by echocardiography), peripheral neuropathy or liver amyloidosis occurred in 14, 12, 3, and 1, respectively. Echocardiography demonstrated an interventricular septal thickness ≥15 mm in six patients, five of whom died post transplantation. Three patients died of progressive amyloidosis at 7, 7, and 21 months. Thirteen patients are alive with a follow-up of 3 to 26 months. Twelve (60{\%}) fulfilled the criteria of a hematologic or organ response. Severe gastrointestinal tract toxicity was seen in five (25{\%}). We conclude that blood cell transplantation for amyloidosis had a much higher morbidity and mortality compared with transplantation for myeloma. The best results appear to occur in patients with nephrotic syndrome as the only manifestation of their disease.",
keywords = "Amyloidosis, Congestive heart failure, Monoclonal protein, Multiple myeloma, Nephrotic syndrome, Stem cell transplantation",
author = "Morie Gertz and Martha Lacy and Gastineau, {D. A.} and Inwards, {D. J.} and Chen, {M. G.} and Ayalew Tefferi and Kyle, {R. A.} and Litzow, {Mark R}",
year = "2000",
language = "English (US)",
volume = "26",
pages = "963--969",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

AU - Gertz, Morie

AU - Lacy, Martha

AU - Gastineau, D. A.

AU - Inwards, D. J.

AU - Chen, M. G.

AU - Tefferi, Ayalew

AU - Kyle, R. A.

AU - Litzow, Mark R

PY - 2000

Y1 - 2000

N2 - This study investigated the response rate and toxicity of blood cell transplantation as treatment for primary amyloidosis (AL). Twenty-three patients had stem cells collected between November 1995 and September 1998. Conditioning included melphalan and total body irradiation in 16 and melphalan alone in 4. Three patients did not undergo stem cell infusion because of poor performance status. Two died of progressive amyloid at 1 and 3 months. One patient is alive on hemodialysis. Fourteen males and six females (median age, 57 years) underwent transplantation. Renal, cardiac (by echocardiography), peripheral neuropathy or liver amyloidosis occurred in 14, 12, 3, and 1, respectively. Echocardiography demonstrated an interventricular septal thickness ≥15 mm in six patients, five of whom died post transplantation. Three patients died of progressive amyloidosis at 7, 7, and 21 months. Thirteen patients are alive with a follow-up of 3 to 26 months. Twelve (60%) fulfilled the criteria of a hematologic or organ response. Severe gastrointestinal tract toxicity was seen in five (25%). We conclude that blood cell transplantation for amyloidosis had a much higher morbidity and mortality compared with transplantation for myeloma. The best results appear to occur in patients with nephrotic syndrome as the only manifestation of their disease.

AB - This study investigated the response rate and toxicity of blood cell transplantation as treatment for primary amyloidosis (AL). Twenty-three patients had stem cells collected between November 1995 and September 1998. Conditioning included melphalan and total body irradiation in 16 and melphalan alone in 4. Three patients did not undergo stem cell infusion because of poor performance status. Two died of progressive amyloid at 1 and 3 months. One patient is alive on hemodialysis. Fourteen males and six females (median age, 57 years) underwent transplantation. Renal, cardiac (by echocardiography), peripheral neuropathy or liver amyloidosis occurred in 14, 12, 3, and 1, respectively. Echocardiography demonstrated an interventricular septal thickness ≥15 mm in six patients, five of whom died post transplantation. Three patients died of progressive amyloidosis at 7, 7, and 21 months. Thirteen patients are alive with a follow-up of 3 to 26 months. Twelve (60%) fulfilled the criteria of a hematologic or organ response. Severe gastrointestinal tract toxicity was seen in five (25%). We conclude that blood cell transplantation for amyloidosis had a much higher morbidity and mortality compared with transplantation for myeloma. The best results appear to occur in patients with nephrotic syndrome as the only manifestation of their disease.

KW - Amyloidosis

KW - Congestive heart failure

KW - Monoclonal protein

KW - Multiple myeloma

KW - Nephrotic syndrome

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0033758844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033758844&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 963

EP - 969

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -